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in the vascular endothelium of human endometrium and myometrium (Telfer et al., 1997) . Based on a recent report 3 To whom correspondence should be addressed (Smith and Brien, 1998) , and on anecdotal obstetric uses of Endometrial growth is thought to depend on uterine artery nitroglycerine (NTG), a NO donor, for uterine relaxation and blood flow and the importance of endometrial development tocolysis, we speculated that NTG could be used to improve on in-vitro fertilization (IVF) outcome has been previously endometrial development. Treatment with NTG patches did reported. Nitric oxide (NO) relaxes vascular smooth muscle produce a trilaminar sonographic pattern and increased endothrough a cGMP-mediated pathway and NO synthase metrial thickness, but was impractical due to an unacceptably isoforms have been identified in the uterus. Sildenafil citrate high rate of headaches, nausea and hypotension. (Viagra), a type 5-specific phosphodiesterase inhibitor, augPhosphodiesterase (PDE) is a family of isoenzymes that ments the vasodilatory effects of NO by preventing the hydrolyse cAMP and cGMP. Specific inhibitors of PDE subdegradation of cGMP. In this preliminary report we types have been identified that can augment the effects of describe the use of vaginal sildenafil to improve uterine cyclic nucleotides on target tissues, such as human spermatozoa artery blood flow and sonographic endometrial appearance (Fisch et al., 1998) . Sildenafil citrate (Viagra) is a newly in four patients with prior failed assisted reproductive developed, type 5-specific PDE inhibitor that prevents the cycles due to poor endometrial response. The uterine artery breakdown of cGMP and potentiates the effects of NO on pulsatility index (PI) was measured in a mock cycle after vascular smooth muscle. Since its introduction in 1997, sildenpituitary down-regulation with Lupron. The PI was afil has been used with great success in the treatment of male decreased after 7 days of sildenafil (indicating increased erectile dysfunction (Boolell et al., 1996) , but as yet no one blood flow) and returned to baseline following treatment has evaluated its effects in women. with placebo. The combination of sildenafil and oestradiol
The availability of sildenafil has enabled us to reap the valerate improved blood flow and endometrial thickness in benefits of NO on the uterus, while minimizing side-effects. all patients. These findings were reproduced in an ensuing
In this report we describe four patients treated with IVF, who gonadotrophin-stimulated cycle. Three of the four patients each had at least three previous failed assisted reproduction conceived. Although greater numbers of patients and rancycles (IVF and/or intrauterine insemination), with good domized evaluation are needed to validate this treatment, ovarian stimulation and a poor endometrial response, who vaginal sildenafil may be effective for improving uterine showed marked improvement in uterine artery blood flow andIntroduction cycle after pituitary down-regulation for 10-14 days with Lupron (TAP Pharmaceuticals, Inc., Deerfield, IL, USA). Baseline measurement of A trilaminar sonographic endometrial pattern of ജ8 mm on uterine artery blood flow (pulsatility index, PI) was recorded using the day of human chorionic gonadotrophin (HCG) has been Doppler ultrasound (LOGIQ 400, GE Medical Systems, Milwaukee,  shown to be correlated with a high chance of pregnancy in WI, USA) ( Figure 1A ).
patients being treated with IVF (Gonen et al., 1990; Patients self-administered sildenafil (Pfizer Inc., New York, NY, et al., 1991) . Several regimens have been proposed to improve a USA) suppositories, prepared for us from oral tablets by a local poor endometrial response, including treatment with oestrogens pharmacy, 25 mg intravaginally, four times per day for 7 days. PI and low dose aspirin (Sher et al., 1993; Weckstein et al., and endometrial thickness were evaluated at 168 h. Sildenafil was 1997). In the past few years, much interest has been focused then discontinued and each patient received placebo suppositories for on the role of nitric oxide (NO) as a modulator of uterine 7 days and blood flow parameters were remeasured. Each patient then received a combination of sildenafil suppositories 25 mg intravaginally blood flow (Amit et al., 1998; Cameron and Campbell, 1998 four times per day and oestradiol valerate 4 mg i.m., twice per week and uterine artery blood flow were begun on cycle day 9 ( Figure  1B ). Ovulation was triggered with 10 000 IU HCG (Profasi; Serono) for 8 days, at which time PI and sonographic endometrial appearance were re-evaluated. Sildenafil and oestradiol were then stopped, when two lead follicles were ജ18 mm in diameter and half the remainder were at least 15 mm. Oocytes were retrieved transvaginally while the Lupron was continued and the patient experienced a menstrual bleed.
under ultrasound guidance, 35 h later. Metaphase II oocytes underwent intracytoplasmic sperm injection Controlled ovarian hyperstimulation was then begun using Gonal-F (Serono Laboratories, Norwell, MA, USA) in an initial dose of (ICSI) 4-5 h after retrieval. Resulting embryos were cultured to the blastocyst stage, at which point two embryos were transferred to the 300-375 IU, which was decreased by 150 IU on the third day of stimulation. At the same time sildenafil suppositories, 25 mg four uterus. Progesterone in oil, 50 mg i.m. twice daily, was used for luteal support. Serum βHCG concentrations were obtained 11 and 13 times per day, were restarted and were continued until the day of HCG administration (8-12 days). Oestradiol concentrations and days after oocyte retrieval. A viable pregnancy was defined by fetal cardiac activity on ultrasound examination at 6-7 weeks of gestation. ultrasonographic monitoring of folliculogenesis, endometrial pattern a At each examination, multiple measurements of the lining were made by the same person until a consensus was reached. The error was Ͼ0.1 mm but Ͻ0.5 mm. Therefore measurements were rounded to the nearest whole number. DES ϭ diethylstilboestrol; IUI ϭ intrauterine insemination. PI ϭ pulsatility index; ET ϭ endometrial thickness; L ϭ Lupron; E 2 V ϭ oestradiol valerate; FSH ϭ follicle stimulating hormone (Gonal-F); HCG ϭ human chorionic gonadotrophin; R ϭ right; L ϭ left.
Results

Discussion
The four patients ranged in age between 31 and 37 years
The importance of endometrial appearance as a predictor of (Table I) . They suffered from a range of uterine disorders outcome in patients treated with IVF is well established (Gonen including, diethylstilboestrol (DES) exposure, adenomyosis, and Casper, 1990; Sher et al., 1991 Sher et al., , 1993 . However, treatment and intrauterine synechiae following a hysteroscopic septoplawith oestrogens alone does not appear to improve pregnancy sty. Prior to treatment with sildenafil all four patients experirates significantly in patients with poor endometrial response. enced multiple failed cycles of IVF and/or intrauterine NO is recognized as a mediator of vascular smooth muscle insemination (IUI) with a maximum endometrial thickness of dilatation in many areas of the body. NTG has long been used Ͻ8 mm.
for its vasodilatory properties in the treatment of angina, as The PI ranged between 2.0 and 3.4 after down-regulation well as obstetrically, to achieve tocolysis and uterine relaxation. with Lupron and decreased to between 1.5 and 2.7 after 7
We have used NTG successfully to improve uterine artery days of sildenafil, reflecting increased diastolic flow (Figure 1 blood flow and endometrial lining in IVF patients with a and Table II ). The PI returned to baseline after 7 days of previous poor response. However, we experienced a high rate placebo. The PI was again markedly decreased following of side-effects, including hypotension and headaches. The use 7 days of sildenafil/oestradiol valerate and the endometrial of intravaginal sildenafil suppositories made it possible to thickness developed to Ͼ10 mm in three of the four patients.
decrease the incidence of these side-effects by delivering These findings were reproduced in an ensuing gonadotrophinmedication in close proximity to the target organ. stimulated cycle (Table II) . Three patients ultimately became
All of the patients reported here had at least three prior failed pregnant. One patient could not be stimulated to produce an assisted reproduction cycles with good ovarian stimulation, and endometrial lining of Ͼ8 mm, despite improvement of her PI.
none achieved a lining Ͼ8 mm despite previous treatment She had a history of synechiae following the resection of a with oestrogen. Using a cross-over study design, we demonuterine septum and this patient was the only one who did not strated the ability of sildenafil to modulate uterine artery blood conceive. There were no complaints of side-effects from any flow and improve endometrial pattern and thickness. Three of the four patients conceived. The one who did not, had of the four patients. Telfer, J.F., Irvine, G.A., Kohnen, G. et al. (1997) demonstrates that no one factor can explain all implantation failures.
Received on September 17, 1999; accepted on December 15, 1999 While improving uterine blood flow in the proliferative phase, NO may have detrimental effects at the level of the endometrium during the implantation window. The NOmediated release of cytokines such as tumour necrosis factor-α from activated natural killer cells has been implicated as a cause of implantation failure (Barroso et al., 1998) . It may be beneficial to minimize endometrial NO exposure at the time of embryo transfer and we recommend discontinuing sildenafil supplementation on or prior to the day of HCG administration.
The four patients presented here were strictly monitored with a rigorous protocol that used each patient as her own control. Due to the nature of our practice, the ultrasonographer could not be blinded to the treatment conditions. However, the data were collected in the same manner at all evaluations and the manner of data collection did not affect the outcomes. While these numbers are too small to make generalizations regarding pregnancy rates, a definite improvement in uterine artery blood flow and endometrial development was seen in all patients, and three out of four patients conceived after treatment with sildenafil. Since our initial investigation, we have used sildenafil to improve the uterine artery blood flow and endometrial appearance in more than 20 additional patients with promising results. However, before recommending its widespread use, the benefits of sildenafil should be evaluated in a randomized manner and further investigation is warranted.
